Search

Your search keyword '"Arance, Ana"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Arance, Ana" Remove constraint Author: "Arance, Ana" Database OpenAIRE Remove constraint Database: OpenAIRE
40 results on '"Arance, Ana"'

Search Results

1. COLUMBUS 5-year update : a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF

2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

3. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

4. Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’

5. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

6. Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series

7. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

8. Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma

9. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)

10. Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238

11. 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

12. Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma (Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA.)

13. Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

15. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

16. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma

17. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238)

18. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

19. Dabrafenib plus trametinib for compassionate use in metastatic melanoma

20. FC1-3: Does Phototherapy Induce Melanoma Simulators? Role of Confocal Microscopy in the Evaluation of Nevi Undergoing nbUVB Irradiation

21. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

22. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFmutation-positive metastatic melanoma

23. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

24. Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

25. Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma

26. Pembrolizumab versus Ipilimumab in Advanced Melanoma

27. Additional file 1: Table S1. of Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

28. Guía de estudios y profesiones

29. Guía de estudios y profesiones

31. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

32. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)

33. FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A)

34. Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma

36. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

37. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma

38. An open-label, multicentre safety study of vemurafenib in patients with BRAFⱽ⁶⁰⁰-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

39. Dabrafenib plus trametinib for compassionate use in metastatic melanoma

40. Guía de estudios y profesiones

Catalog

Books, media, physical & digital resources